PHASQ Stock Crashes 99% on Pink Sheets, Bankruptcy Aftermath

PHASQ stock is trading at just $0.000001 USD on the PNK (Pink Sheets) exchange as of April 17, 2026. The biotech company has collapsed 99% from its year high of $0.0399. PhaseBio Pharmaceuticals filed for Chapter 11 bankruptcy in October 2022, leaving shareholders with minimal recovery prospects. The stock now trades with extremely low volume and liquidity. This represents one of the most severe losses in the healthcare sector. Investors should understand the company’s bankruptcy status before considering any positions in PHASQ stock.

What Happened to PHASQ Stock Price

PHASQ stock has experienced a catastrophic decline. The stock trades at $0.000001, down from a previous close of $0.0001. Over the past year, PHASQ stock has lost 99.99% of its value. The year-to-date performance shows similar devastation. Daily volume sits at just 2,500 shares, compared to an average of 22,310 shares. This extreme illiquidity makes it nearly impossible to buy or sell meaningful positions. The 50-day moving average stands at $0.000236, while the 200-day average is $0.000666, both far above current trading levels.

PhaseBio’s Bankruptcy Filing and Current Status

PhaseBio Pharmaceuticals filed a voluntary Chapter 11 petition on October 23, 2022, in the U.S. Bankruptcy Court for the District of Delaware. The company was developing cardiovascular treatments, including bentracimab (PB2452), a reversal agent for ticagrelor. Despite having a co-development agreement with SFJ Pharmaceuticals X, Ltd., the company could not sustain operations. The bankruptcy effectively ended shareholder value. Track PHASQ on Meyka for real-time updates on any restructuring developments. The company’s headquarters remain in Malvern, Pennsylvania, though operations have ceased.

Financial Metrics Show Severe Distress

PHASQ’s financial metrics reflect the company’s dire situation. Earnings per share stand at -$2.14, indicating massive losses. The price-to-earnings ratio is essentially meaningless at -0.00000047. Operating cash flow per share is -$1.61, showing the company burned cash rapidly. Free cash flow per share reached -$1.70. The company reported zero market capitalization and negative book value per share of -$3.16. These metrics confirm PHASQ stock has no fundamental value. The company’s enterprise value is negative at -$33.96 million, reflecting liabilities exceeding assets.

Market Sentiment and Trading Activity

Trading activity in PHASQ stock remains minimal. Daily volume of 2,500 shares represents just 11.2% of the average volume. This extreme illiquidity creates significant bid-ask spreads and execution risk. The stock trades on the Pink Sheets (PNK), a lower-tier exchange with minimal regulatory oversight. Most institutional investors avoid penny stocks like PHASQ. Retail traders occasionally speculate on bankruptcy recovery plays, but realistic recovery prospects are near zero. The stock’s penny status reflects its status as a distressed security with no operating business.

Meyka AI Stock Grade and Analysis

Meyka AI rates PHASQ with a grade of C+ based on a score of 59.26 out of 100. The rating suggests a HOLD position, though this applies only to existing shareholders. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The relatively neutral grade reflects the stock’s bankruptcy status and lack of recovery catalysts. However, these grades are not guaranteed, and Meyka AI is not a financial advisor. Investors should conduct thorough due diligence before making any decisions regarding distressed securities.

Why PHASQ Stock Remains a Speculative Play

PHASQ stock trades as a speculative bankruptcy recovery play with minimal probability of shareholder recovery. The company’s pipeline included promising cardiovascular treatments, but development halted post-bankruptcy. Creditors will receive priority in any asset liquidation or restructuring. Common shareholders typically recover nothing in Chapter 11 cases. The stock’s penny status reflects realistic expectations. Any recovery would require a dramatic turnaround, asset sales, or acquisition by another entity. Current trading represents pure speculation rather than fundamental investing. Most financial advisors recommend avoiding PHASQ stock entirely.

Final Thoughts

PHASQ stock represents a cautionary tale in biotech investing. Trading at $0.000001 USD on the Pink Sheets, the stock has lost 99% of its value following PhaseBio’s October 2022 bankruptcy filing. The company’s financial metrics show severe distress with negative earnings, cash flow, and book value. Trading volume remains extremely low at just 2,500 shares daily, creating liquidity challenges. Meyka AI assigns a C+ grade with a HOLD recommendation, though this reflects the stock’s distressed status rather than investment potential. Shareholders face minimal recovery prospects in the bankruptcy process. This stock exemplifies the risks of clinical-stage biotech companies dependent on successful drug development. Investors should avoid PHASQ stock unless they fully understand bankruptcy recovery dynamics and can afford total loss of capital.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.